Epithelioid Sarcoma

Observed

→ investigated in trials for

Tazemetostatsmall_molecule

6 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ifosfamidesmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pazopanibsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cixutumumabmonoclonal antibody

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cemiplimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dasatinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ribociclibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Romidepsinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selinexorsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Talimogene Laherparepvecgene therapy

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trabectedinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vismodegibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Zoledronic Acidsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Epithelioid Sarcoma studied in …STUDIED_INderived10 of 33show all (up to 200)
→ studied in	NCT06444880Phase 2 · active not recruiting Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06239272Phase 1/Phase 2 · recruiting NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03069378Phase 2 · active not recruiting A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05286801Phase 1/Phase 2 · active not recruiting Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03874455no longer available Tazemetostat Expanded Access Program for Adults With Solid Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04225429no longer available Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04416568Phase 2 · active not recruiting Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06625190Phase 1/Phase 2 · recruiting Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02180867Phase 2/Phase 3 · completed Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05407441Phase 1/Phase 2 · active not recruiting Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)	—	—	Epithelioid Sarcoma	1	Observed	clinicaltrials	graph →

Epithelioid Sarcoma studied in …STUDIED_INderived10 of 33show all (up to 200)

→ studied in

NCT06444880Phase 2 · active not recruiting

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT06239272Phase 1/Phase 2 · recruiting

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT03069378Phase 2 · active not recruiting

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT05286801Phase 1/Phase 2 · active not recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT03874455no longer available

Tazemetostat Expanded Access Program for Adults With Solid Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT04225429no longer available

Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT04416568Phase 2 · active not recruiting

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT06625190Phase 1/Phase 2 · recruiting

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT02180867Phase 2/Phase 3 · completed

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed

→ studied in

NCT05407441Phase 1/Phase 2 · active not recruiting

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · condition mapped ONTOLOGY_EXACT · 33 trials mapped (11 active)

—

Observed